Overview

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer
Phase:
Phase 3
Details
Lead Sponsor:
German Breast Group
Collaborators:
Amgen
Celgene
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Epirubicin
Paclitaxel